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Background: In the multicentre randomized trial BRIOS (Breast Reconstruction In One Stage),
direct-to-implant (DTI) breast reconstruction with an acellular dermal matrix (ADM) was associated
with amarkedly higher postoperative complication rate compared with two-stage tissue expander/implant
breast reconstruction. This study aimed to identify factors that contribute to the occurrence of compli-
cations after DTI ADM-assisted breast reconstruction.
Methods: Data were obtained from the BRIOS study, including all patients treated with DTI
ADM-assisted breast reconstruction. Logistic regression analyses were performed to identify factors pre-
dictive of postoperative complications.
Results: Fifty-nine patients (91 breasts) were included, of whom 27 (35 breasts) developed a surgical
complication. Reoperations were performed in 29 breasts (32 per cent), with prosthesis removal in 22
(24 per cent). In multivariable analyses, mastectomy weight was associated with complications (odds
ratio (OR) 1⋅94, 95 per cent c.i. 1⋅33 to 2⋅83), reoperations (OR 1⋅70, 1⋅12 to 2⋅59) and removal of the
implant (OR 1⋅55, 1⋅11 to 2⋅17). Younger patients (OR 1⋅07, 1⋅01 to 1⋅13) and those who received adjuvant
chemotherapy (OR 4⋅83, 1⋅15 to 20⋅24) more frequently required reoperation. In univariable analyses,
adjuvant radiotherapy showed a trend towards more complications (OR 7⋅23, 0⋅75 to 69⋅95) and removal
of the implant (OR 5⋅12, 0⋅76 to 34⋅44), without reaching statistical significance.
Conclusion: Breast size appeared to be the most significant predictor of complications in DTI
ADM-assisted breast reconstruction. The technique should preferably be performed in patients with
small to moderate sized breasts. Registration number: NTR5446 (http://www.trialregister.nl).
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Introduction
The use of acellular dermal matrices (ADMs) in
implant-based breast reconstruction (IBBR) has increased
rapidly over the past two decades1,2. The dermal matrix
is mainly used to provide inferolateral implant coverage,
which allows a larger implant to be inserted and decreases
pectoralis major retraction. This is thought to reduce
postoperative pain and to enhance aesthetic outcome.
In the longer term, reduced capsular contracture rates
have been reported after IBBR in combination with an
ADM2–4. ADMs may be used in both direct-to-implant
(DTI) IBBR and a two-stage expander/implant-based
reconstruction. Although several articles have reported
on the outcomes of ADM-assisted IBBR, evidence for
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the suggested advantages is still limited1. Moreover,
evidence for the safety of ADM use in IBBR is also sparse,
with contradictory results. Complication rates in published
studies1,5–8 vary widely from 4⋅0 to 50⋅0 per cent. Reported
complications include haematoma, seroma, infection, skin
necrosis, flap or nipple ischaemia, and exposure of the
ADM or implant5–7. Several factors have been reported to
increase the risk of complications, including age, smoking,
BMI exceeding 30 kg/m2, periareolar incision, mastectomy
weight over 600 g, and implant size larger than 600ml5,7,9.
To optimize patient selection and treatment, it is impor-
tant to discern which factors affect the outcomes of
ADM-assisted IBBR, thereby reducing complication
and rates of implant removal. The BRIOS study was an
open-label phase IV multicentre RCT that compared DTI
breast reconstruction combined with ADM and a conven-
tional two-stage expander/implant breast reconstruction
(without ADM)10. The early postoperative complication
rate was significantly higher in the DTI ADM-assisted
group than the two-stage group (38⋅5 versus 14⋅1 per cent;
odds ratio (OR) 3⋅81; P< 0⋅001). A high rate of wound
healing problems was observed, leading to implant loss
in 26⋅6 per cent of breasts10. The aim of the present
study was to identify factors that contributed to the occur-
rence of adverse outcomes in DTI ADM-assisted breast
reconstruction.
Methods
In the BRIOS trial, DTI ADM-assisted breast recon-
struction using Strattice Tissue Reconstructive Matrix™
(LifeCell, Branchburg, New Jersey, USA) was compared
with conventional two-stage tissue expander/implant
IBBR. The primary endpoint was health-related quality of
life assessed with the BREAST-Q at 1 year after placement
of the definitive implant. Secondary outcomes were the
incidence of perioperative and postoperative complica-
tions, aesthetic outcome, pain, and burden on the patients
in terms of number of procedures and time invested. The
protocol was approved by the institutional review board at
each study centre. All patients provided written informed
consent. The study was performed in accordance with the
Declaration of Helsinki and guidelines for Good Clinical
Practice. The full study design and methodology have
been described previously10. The study was preregistered
in the Netherlands Trial Register (NTR5446). Owing to
worries about safety, just after the final patient had been
enrolled in the BRIOS study, but before seven women had
undergone surgery, the Dutch Health Care Inspectorate
requested a preliminary safety analysis. The early safety
outcomes have been reported previously10. The aim of the
present study was to identify factors contributing to the
occurrence of adverse outcomes in DTI ADM-assisted
breast reconstruction. Therefore, no preregistered analysis
plan was available.
Patient selection and data collection
Patients included in the BRIOS study who underwent DTI
breast reconstruction with the additional use of an ADM
were included in the present study. Patient demographics
and possible risk factors for adverse events were extracted
from the study database and medical charts, including
data on surgical techniques and the postoperative course.
All adverse events and their subsequent course and man-
agement were reviewed in detail. Cultures after implant
removal were reported if available. The final complication
and reoperation rate per patient was scored. For example,
if a necrosectomy was performed that eventually led to
removal of the implant, this was scored as implant loss.
Outcome measures
Adverse events were grouped into three categories: occur-
rence of any surgical complication; reoperation after a
surgical complication; and removal of the implant and/or
ADM after a surgical complication. Complications were
graded according to the Common Terminology Criteria
for Adverse Events (CTCAE), in which grade 1 and 2 cor-
respond to mild or moderate adverse events, and grade 3
to severe adverse events requiring serious interventions11.
There were no grade 4 or 5 events. The time frame for
registration of postoperative complications was the entire
study follow-up, 1 year after placement of the definitive
implant.
Patient-related factors included in the analyses were:
age, BMI, diabetes mellitus, history of smoking (yes or
no), neoadjuvant chemotherapy and adjuvant chemother-
apy, radiotherapy, hormone therapy and targeted therapy.
Surgery-related factors were: type of incision, skin-sparing
or nipple-sparing mastectomy, axillary surgery including
sentinel node biopsy or axillary lymph node dissection,
mastectomy weight, size of the prosthesis, and the rela-
tionship between mastectomy weight and weight of the
prosthesis. Nipple-sparing mastectomies were performed
via an incision in the inframammary fold (IMF). Other
incision types were both nipple- and skin-sparing mastec-
tomies and comprised only a horizontal component, inci-
sions with a vertical or diagonal component including the
nipple–areola complex, or a boomerang and a wise pattern
incision (inverted-T incision). To identify a learning curve
effect, patients were divided into three consecutive groups
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Table 1 Patient demographics and clinical data
No. of patients*
(n = 59)
Age (years)† 43⋅5(11⋅7)
Body mass index (kg/m2)† 23⋅4(2⋅9)
Treatment
Unilateral 27 (46)
Bilateral 32 (54)
Indication for surgery
Prophylactic 21 (36)
Therapeutic 38 (64)
Smoker 12 (20)
Diabetes mellitus 2 (3)
Previous breast surgery‡ n = 91
None 85 (93)
Excision cyst 1 (1)
Lumpectomy, benign 1 (1)
Lumpectomy, malignant 4 (4)
Chemotherapy
Preoperative 7 (12)
Postoperative 15 (25)
Radiotherapy (adjuvant) 6 (10)
Hormone therapy 19 (32)
Targeted therapy 3 (5)
Follow-up after surgery (months)† 24⋅7(7⋅1)
*With percentages in parentheses unless indicated otherwise; †values are
mean(s.d.); ‡number of breasts.
Table 2 Surgical characteristics
No. of breasts*
(n = 91)
Type of axillary surgery
None 50 (55)
Sentinel lymph node biopsy 35 (38)
Axillary lymph node dissection 6 (7)
Nipple-sparing mastectomy 35 (38)
IMF incision 21 (23)
Incision without vertical component 7 (8)
Vertical/diagonal 6 (7)
Wise pattern 1 (1)
Skin-sparing mastectomy 56 (62)
Incision without vertical component 49 (54)
Vertical/diagonal 7 (8)
Mastectomy weight (g) (n = 87) 365 (260–453)
Implant weight (n = 90) 370 (335–445)
Mastectomy weight – implant weight (g) (n = 87) –19 (–100 to 32)
*With percentages in parentheses unless indicated otherwise; †values are
median (i.q.r.).
of 30–31 reconstructions based on the date of surgery
(early, middle and late).
Statistical analysis
Univariable and multivariable logistic generalized estimat-
ing equation (GEE) analyses were performed to determine
the predictive value of patient- and surgery-related factors
for the occurrence of a surgical complication, reoperation
Table 3 Adverse outcomes
No. of breasts
(n = 91)
Complications
No surgical complication 56 (62)
Haematoma 3 (3)
Red breast syndrome 5 (5)
Wound infection 7 (8)
Skin necrosis 11 (12)
Wound dehiscence with exposure of 8 (9)
ADM 5 (5)
ADM + implant 2 (2)
Unknown 1 (1)
Incomplete resection* 1 (1)
Reoperation for surgical complications
No reoperation for surgical reasons 62 (68)
Haematoma evacuation 3 (3)
Botulinum toxin injection 1 (1)
Necrosectomy 1 (1)
Removal of implant 24 (27)
ADM 2 (2)
Implant only 10 (11)
ADM + implant 12 (13)
Values in parentheses are percentages. ADM, acellular dermal matrix.
*Complication regardless of the reconstruction method.
and implant removal. Because data were analysed per
breast, GEEs were used to adjust for the dependency of
the observations within one patient. Factors with univari-
able P< 0⋅200 were selected for multivariable GEE analy-
ses. A backward selection procedure was used to obtain the
final models for the three outcomes, in which only variables
with P< 0⋅100 were selected. In addition, possible associa-
tions between date of surgery and adverse outcomes were
assessed by means of logistic GEE analyses. Two-sided
P< 0⋅050 was considered statistically significant. SPSS®
version 22 (IBM, Armonk, New York) was used for the
analyses.
Results
In total, 59 women (91 breasts) who underwent DTI
ADM-assisted breast reconstructionwere included.Demo-
graphic data are shown in Table 1. The patients had a
mean(s.d.) age of 43⋅5(11⋅7) (range 25–71) years and a
BMI of 23⋅4(2⋅9) (range 18⋅3–31⋅8) kg/m2. There were
21 prophylactic and 38 therapeutic mastectomies. Adju-
vant radiotherapy was administered in six breasts (7 per
cent). One incomplete resection was noted (unrelated to
the reconstruction), for which a second procedure was
performed. Mean clinical follow-up was 24⋅7(7⋅1) (range
11–37) months.
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Table 4 Univariable logistic regression analyses of factors influencing outcomes
Any complication
(n = 35 reconstructions)
Any reoperation
(n = 29 reconstructions)
Any removal of ADM and/
or implant (n = 24
reconstructions)
Factor Odds ratio P Odds ratio P Odds ratio P
Age (years) 1⋅0 (0⋅96, 1⋅05) 0⋅773 1⋅03 (0⋅99, 1⋅09) 0⋅145 1⋅04 (0⋅99, 1⋅01) 0⋅151
BMI (kg/m2) 1⋅08 (0⋅91, 1⋅28) 0⋅371 1⋅00 (0⋅84, 1⋅19) 0⋅999 1⋅06 (0⋅89, 1⋅28) 0⋅501
Smoking 0⋅89 (0⋅30, 2⋅65) 0⋅832 0⋅64 (0⋅19, 2⋅23) 0⋅488 0⋅68 (0⋅16, 2⋅84) 0⋅593
Diabetes mellitus 2⋅26 (0⋅12, 38⋅64) 0⋅573 3⋅06 (0⋅18, 52⋅48) 0⋅441 3⋅63 (0⋅21, 62⋅96) 0⋅376
Previous breast surgery 1⋅06 (0⋅78, 1⋅42) 0⋅711 –* –*
Chemotherapy
Preoperative 0⋅70 (0⋅20, 2⋅36) 0⋅560 0⋅67 (0⋅16, 2⋅81) 0⋅585 0⋅86 (0⋅21, 3⋅55) 0⋅839
Postoperative 2⋅03 (0⋅63, 6⋅56) 0⋅235 2⋅27 (0⋅69, 7⋅47) 0⋅177 1⋅65 (0⋅47, 5⋅91) 0⋅435
Adjuvant radiotherapy 7⋅23 (0⋅75, 69⋅95) 0⋅087 3⋅61 (0⋅55, 23⋅77) 0⋅181 5⋅12 (0⋅76, 34⋅44) 0⋅093
Hormone therapy 1⋅46 (0⋅54, 3⋅99) 0⋅457 0⋅84 (0⋅27, 2⋅62) 0⋅769 0⋅88 (0⋅26, 2⋅98) 0⋅834
Targeted therapy –† –† –†
Incision technique 0⋅152
IMF 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Other‡ 1⋅40 (0⋅49, 3⋅99) 0⋅527 3⋅56 (0⋅79, 15⋅95) 0⋅097 8⋅75 (0⋅45, 170⋅96)
Nipple-sparing mastectomy
Yes 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
No 0⋅56 (0⋅20, 1⋅55) 0⋅266 0⋅63 (0⋅22, 1⋅84) 0⋅400 0⋅55 (0⋅17, 1⋅80) 0⋅332
Mastectomy weight (g)§ 1⋅94 (1⋅33, 2⋅82) < 0⋅001 1⋅54 (1⋅09, 2⋅20) 0⋅015 1⋅55 (1⋅11, 2⋅17) 0⋅010
Mastectomy weight – implant weight (g)§ 1⋅33 (0⋅92, 1⋅92) 0⋅126 1⋅18 (0⋅82, 1⋅71) 0⋅336 1⋅18 (0⋅80, 1⋅73) 0⋅397
Values in parentheses are 95 per cent confidence intervals. Ninety-one breasts were included in the analyses. *None of the patients who had undergone
breast surgery previously were reoperated. †All patients who underwent targeted therapy had complications, reoperations and implant removal. ‡All
incisions other than an incision in the inframammary fold (IMF). §Odds ratio calculated for a 100-g weight difference. ADM, acellular dermal matrix.
Table 5 Multivariable logistic regression analyses of factors influencing outcomes
Any complication
(n = 35 reconstructions)
Any reoperation
(n = 29 reconstructions)
Any removal of ADM and/
or implant (n = 24
reconstructions)
Odds ratio P Odds ratio P Odds ratio P
Age (years) – 1⋅07 (1⋅01, 1⋅13) 0⋅026 –
Postoperative chemotherapy – 4⋅83 (1⋅15, 20⋅24) 0⋅031 –
Mastectomy weight (g)* 1⋅94 (1⋅33, 2⋅83) < 0⋅001 1⋅70 (1⋅12, 2⋅59) 0⋅014 1⋅55 (1⋅11, 2⋅17) 0⋅010
Values in parentheses are 95 per cent confidence intervals. Ninety-one breasts were included in the analyses. *Odds ratio calculated for a 100-g weight
difference. ADM, acellular dermal matrix.
Surgical characteristics
The incision for the mastectomy was made at the IMF
only in 21 breasts (23 per cent), and a nipple-sparing
mastectomywas performed in 35 (38 per cent). Themedian
mastectomy weight was 365 (i.q.r. 260–453) g. On aver-
age, implanted prostheses were comparable to the volume
of mastectomy weight resected, with a median weight of
inserted prosthesis of 370 (335–445) g, and a median dif-
ference of –19 (–100 to 32) g (Table 2).
Complications, reoperations and implant removals
Only complications that occurred during the first year
after placement of the definite implant were included in
the analyses. Complications mainly occurred in the first
month after surgery, a median of 13⋅5 (range 1–350)
days (mean(s.d.) 33⋅4(70⋅8) days) after surgery. Surgical
complications developed in 27 (46 per cent) of the 59
women (35 breasts, 38 per cent). Complications are listed
in Table 3. Reoperation was necessary in 22 patients (37 per
cent) (29 breasts, 32 per cent) for haematoma evacuation
(3), necrosectomy (1), botulinum toxin injection for breast
animation deformity (1), and removal of the ADM (2),
the implant (10) or both (12). One case of incomplete
resection was reported.
Univariable and multivariable analyses
The results of univariable and multivariable logistic
GEE analyses are shown in Tables 4 and 5 respectively.
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Because all three patients (3 breasts) who received targeted
trastuzumab therapy had complications and subsequent
implant removal, and none of the six patients who had
undergone previous breast surgery had a reoperation,
these two variables were not included in the GEE
analyses.
In the final multivariable model, a greater mastectomy
weight was associated with a higher complication rate (OR
1⋅94, 95 per cent c.i. 1⋅33 to 2⋅83; P< 0⋅001), more reoper-
ations (OR 1⋅70 1⋅12 to 2⋅59; P = 0⋅014) and more implant
removals (OR 1⋅55, 1⋅11 to 2⋅17; P= 0⋅010). Younger
patients were at higher risk of reoperation owing to com-
plications (OR 1⋅07, 1⋅01 to 1⋅13; P= 0⋅026). Furthermore,
adjuvant chemotherapy resulted in more reoperations (OR
4⋅83, 1⋅15 to 20⋅24; P = 0⋅031).
Association with learning curve
The first 30 breast reconstructions were performed
between 18 April 2013 and 6 January 2014, the following
31 between 23 January 2014 and 25 July 2014, and the final
30 reconstructions between 1 September 2014 and 24 June
2015. Although severe adverse events (CTCAE grade 3)
were common at the beginning of the study, there were no
statistically significant differences between patients who
underwent surgery in the early phase and those operated
later in the study (Table S1, supporting information).
Association with bacterial cultures
Removal of the implant was necessary in 17 patients (24
breasts) with severe complications (CTCAE grade 3). Sam-
ples from 15 patients (19 breasts) were submitted for
microbiological culture. Most cultures were sterile (11) or
showed only commensal skin flora (4). Abnormal bacte-
rial cultures were found in four patients (4 breasts). No
associations between outcomes and culture results could be
established, owing to the variety of bacterial cultures found
(data not shown).
Discussion
In the BRIOS randomized trial, conventional two-stage
reconstruction was compared with DTI breast reconstruc-
tion with the additional use of an ADM10. A high rate of
complications was found in the DTI ADM-assisted group,
which was at the high end of complication rates reported
in the literature1,5–7. To assess risk factors for adverse
outcomes, clinical outcomes of the 59 patients (91 breast
reconstructions) who underwent DTI ADM-assisted
breast reconstruction were reviewed in detail here. Breast
size, as represented by mastectomy weight, was the most
significant risk factor associated with complications, reop-
erations and removal of implants. Large breast size has
previously been identified as a risk factor for complicated
DTI immediate breast reconstruction. An increased risk
of complications was reported for a mastectomy weight
greater than 600 g5. In the present cohort, increasing
breast size was associated with complications, although
mastectomy weight was below 600 g in 87 of 91 breasts.
Inserting a larger prosthesis than the original breast size
did not result in severe adverse events, indicating that the
higher complication rate was associated primarily with the
initial breast size and not with placement of a larger pros-
thesis. Hunsicker and colleagues7 reported a significant
risk of complications when implants of 600ml or larger
were used. This cannot be verified from the present data,
as implant sizes were smaller in this study. The Association
of Breast Surgery and the British Association of Plastic,
Reconstructive and Aesthetic Surgeons12 recommend the
use of an ADM in patients with small to moderate sized
breasts, defined by Dundas and colleagues13 as no more
than a C-cup. The present results validate these guidelines
with regard to DTI reconstruction using an ADM.
Several factors related to surgical technique have been
suggested to affect outcomes, including incision type and
mastectomy skin flap thickness14. Here, skin flap quality
and thickness were notmeasured, as nomethods were avail-
able for objective measurement of these variables. There-
fore, their effect on the outcomes cannot be assessed. The
location of the incisions could affect wound healing15,16.
Previous studies16–18 showed a higher complication rate
after periareolar or wise pattern incisions compared with
an inframammary or lateral/inferolateral incision. A trend
towards more complications was also noted in the present
study when the incision was other than in the IMF.
The experience of the surgeon with DTI ADM-assisted
breast reconstruction has been mentioned as an important
factor for a successful outcome19. Colwell and colleagues19
described learning as an improved ability of surgeons
to accurately determine the viability of the mastectomy
skin envelope. They carried out a retrospective review
of patients who underwent IBBR, with the experimen-
tal group receiving ADM-assisted DTI breast reconstruc-
tion (331 reconstructions) and the control group two-stage
IBBR without ADM (148). The final choice of type of
surgery was based on intraoperative evaluation of the
perfusion of the mastectomy skin flaps. In the BRIOS
study, treatment allocation was, however, by randomiza-
tion. Although surgeons could decide to deviate from the
protocol if they thought this necessary for safety rea-
sons, only one patient received the two-stage treatment
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instead of the allocated one-stage reconstruction. Because
of the randomized study design, patient selection was not
adapted over the course of the study. Therefore, a learn-
ing effect pertaining to patient selection is not applicable.
Although all surgeons in the BRIOS study were experi-
enced in performing breast reconstructions, learning may
have occurred in terms of surgical technique and postoper-
ative care. The complication rate in three consecutive peri-
ods was therefore assessed, but no significant association
between time interval and complication rates was observed.
Infection-induced hypoxia can compromise skin flap
survival. The risk of infection is up to ten times higher in
patients with cancer undergoing IBBR than in those having
cosmetic augmentation20. Wound infection developed in
seven breasts in the present cohort, leading to removal
of the implant and/or ADM in five instances. Adjuvant
radiotherapy is a known risk factor for adverse outcomes
after breast reconstruction21,22. Adjuvant chemotherapy is
also likely to have a negative effect on wound healing23.
In the present cohort, only the association between adju-
vant chemotherapy and reoperation reached statistical
significance. The lack of significant association between
radiotherapy and adverse events was likely due to the small
number of patients in the cohort who received radiother-
apy. The impact of smoking on complications is well estab-
lished, but was difficult to assess in the present study. Smok-
ing was analysed as a binary variable, with smokers includ-
ing all patients with a history of smoking. The patients were
strongly advised to quit smoking at least 2weeks before
surgery, although this was not verified with a nicotine test.
All complications ultimately leading to implant removal
in the present cohort were related to wound-healing prob-
lems. Impairment of the blood supply to the mastectomy
skin flap is likely the direct cause of such problems. The
hypothesis that wound-healing problems are a result of
poor skin flap perfusion, and consequently mastectomy
skin flap necrosis, finds broad consensus in the field of
breast reconstructive surgery14,22. However, this hypoth-
esis is hard to confirm, because objective measures of
intraoperative skin flap quality or perfusion are still not
available. Some progress has been made using fluorescence
angiography24–26. However, fluorescence angiography is
not yet recommended as standard care, as at present it
is not cost-effective for use in all patients27. To date, the
trained eye of an experienced surgeon is the only available
benchmark. A strong dependency of outcomes on surgeon
experience, especially with regard to patient selection,
could explain why some expert centres report low com-
plication rates but others report a high rate1,5–7. Future
studies should focus on determining an objective, reliable
method for assessment of skin flap quality during surgery.
One hypothesis is that the increased risk of wound com-
plications in a one-stage reconstruction may be inherent
to the use of an ADM, as opposed to synthetic materi-
als. However, ADMs are regularly used in many types of
surgery, without any convincing evidence that they cause an
adverse tissue response28,29. Furthermore, using an ADM
in a two-stage reconstruction is not associated with an
increased complication rate, implying that the high com-
plication rate observed here is primarily associated with
the surgical technique (direct placement of the definitive
implant) and not the ADM30,31. A prospective study com-
paring DTI breast reconstruction with and without the use
of ADM is lacking.
The strength of the BRIOS study is its prospective ran-
domized design. This ensures a comprehensive data set and
prevents selection bias. A weakness of the study is that the
number of patients was rather small. Furthermore, owing
the randomized set-up, patients might not have received
the reconstruction that would have been the surgeons’ first
choice outside a study. The high complication and implant
removal rate in the DTI group implies that stricter patient
selection is warranted for DTI ADM-assisted breast recon-
struction. As mastectomy weight was a significant pre-
dictor of adverse outcomes in DTI ADM-assisted breast
reconstruction, these reconstructions should preferably be
performed only in patients with small to moderate sized
breasts.
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